

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 06:51:30 ON 19 DEC 2006

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 06:51:44 ON 19 DEC 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 17 DEC 2006 HIGHEST RN 915752-60-2

DICTIONARY FILE UPDATES: 17 DEC 2006 HIGHEST RN 915752-60-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10-500840.str



ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

chain bonds :

8-10

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 10-11 10-15 11-12 12-13 13-14
14-15 14-16 15-17 16-18 17-18

exact/norm bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 8-10 10-11 10-15 11-12 12-13
13-14 14-15 14-16 15-17 16-18 17-18

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 ful

FULL SEARCH INITIATED 06:52:15 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 954 TO ITERATE

100.0% PROCESSED 954 ITERATIONS

120 ANSWERS

SEARCH TIME: 00.00.01

L2 120 SEA SSS FUL L1

=> fil caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

166.94

167.15

FILE 'CAPLUS' ENTERED AT 06:52:20 ON 19 DEC 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 Dec 2006 VOL 145 ISS 26
FILE LAST UPDATED: 18 Dec 2006 (20061218/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l2
L3 3 L2

=> d fbib ed abs

DT Patent
LA English
FAN.CNT 1

ED Entered STN: 10 Aug 2006

compos. containing crystalline E 6070 and a acceptable carrier represent

embodiment of the invention. The invention also relates to methods for treating an inflammatory disorder, an autoimmune disorder, or a proliferative disorder comprising the step of administering to a patient in need thereof a therapeutically effective amount of crystalline E

6070. The compound was prepared and characterized by x-ray diffraction studies.
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d fbib ed abs 2

L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:780361 CAPLUS
 DN 141:295778
 TI Preparation of deazapurines for use in pharmaceutical compositions for the treatment of reperfusion injuries, osteoporosis and/or bone metastasis
 IN Daun, Jane; Fields, Scott; Kobayashi, Seichi
 PA Eisai Co., Ltd., Japan
 SO U.S. Pat. Appl. Publ., 178 pp., Cont.-in-part of WO 2003 57,696.
 CODEN: USXKCO
 DT Patent
 LA English
 FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2004186127	A1	20040923	US 2004-753261	20040107
			US 2002-346598P	P 20020107
			WO 2003-US366	A2 20030107
			WO 2003-US366	20030107
WO 2003057696	A1	20030717	WO 2003-US366	20030107
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1707566	A1	20061004	US 2002-346598P	P 20020107
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			EP 2003-729359	A3 20030107


PATENT FAMILY INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FAN 2003:551516				
PI WO 2003057696	A1	20030717	WO 2003-US366	20030107
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LA, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2472479	A1	20030717	US 2002-346598P	P 20020107
			CA 2003-2472479	20030107
			US 2002-346598P	P 20020107
			WO 2003-US366	W 20030107
AU 2003235741	A1	20030724	AU 2003-235741	20030107
			US 2002-346598P	P 20020107

L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 BR 2003006785 A 20041109 WO 2003-US366 W 20030107
 EP 1474425 A1 20041110 BR 2003-6785 20030107
 EP 1474425 B1 20060524 US 2002-346598P P 20020107
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 US 2005124649 A1 20050609 US 2002-346598P P 20020107
 CN 1630657 A 20050622 US 2003-500840 20030107
 JP 2005524621 T 20050818 US 2002-346598P P 20020107
 AT 327236 T 20060615 US 2002-346598P P 20020107
 PT 1474425 T 20060929 US 2002-346598P P 20020107
 EP 1707566 A1 20061004 US 2002-346598P P 20020107
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 WO 2004063336 A2 20040729 US 2002-346598P P 20020107
 WO 2004063336 A3 20040826 EP 2003-729359 A3 20030107
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ
 US 2004186127 A1 20040923 WO 2003-US366 A 20030107
 ZA 2004006272 A 20051116 US 2004-753261 20040107
 NO 2004003290 A 20040922 US 2002-346598P P 20020107
 NO 2004-6272 20040805
 NO 2002-346598P P 20020107
 NO 2004-3290 20040806
 WO 2003-US366 W 20030107

OS MARPAT 141:295778
 ED Entered STN: 24 Sep 2004
 GI

L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB Deazapurines, such as I [R1 = H, NH2, NHMe, NHAc, OH, F, OMe, CN, NHCO2Et;
 R2 = H, NRaRb, ORa, aliphatic, heteroaliph., aryl, heteroaryl, etc.; Ra, Rb = H, aliphatic, heteroaliph., aryl, heteroaryl; R3 = H, CN, halogen, heteroaryl, amino, carbamoyl, etc.], were prepared for treatment of reperfusion injuries, osteoporosis and/or bone metastasis. Thus, deazapurine II was prepared via a multistep synthetic sequence starting from Me indole-5-carboxylate, di-tert-Bu dicarbonate, tributylstannane, 5,6-diamino-4-chloro-2-pyridinyl-carbamic acid Et ester, tri-Et orthocarbonate, and phthalimide. The prepared deazapurines were assayed for cellular cytokine inhibition using human umbilical vein endothelial cells (HUVEC).

=> d fbib ed abs hitstr 3

L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2003:551516 CAPLUS
 DN 139:117268
 TI Preparation of deazapurines for use in pharmaceutical compositions for the treatment of inflammatory, autoimmune and proliferative diseases
 IN Daun, Jane; Davis, Heather A.; Gusovsky, Fabian; Hishinuma, Ieharu; Jiang, Yimin; Kaneko, Toshihiko; Kikuchi, Kouichi; Kobayashi, Seichi; Lescaubeau, Andre; Li, Xiang-Li; Muramoto, Kenzo; Ohl, Norihito; Pesant, Marc; Seletsky, Boris M.; Soejima, Motohiko; Yao, Ye; Yokohama, Hiromitsu; Zhao, Janet Y.; Zheng, Wanjun; Tremblay, Lynda
 PA Eisai Co., Ltd., Japan
 SO PCT Int. Appl., 215 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003057696	A1	20030717	WO 2003-US366	20030107
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LA, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2472479	A1	20030717	US 2002-346598P	P 20020107
AU 2003235741	A1	20030724	US 2002-346598P	P 20020107
BR 2003006785	A	20041109	US 2002-346598P	P 20020107
EP 1474425	A1	20041110	US 2002-346598P	P 20020107
EP 1474425	B1	20060524	US 2002-346598P	P 20020107
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2005124649	A1	20050609	US 2002-346598P	P 20020107
CN 1630657	A	20050622	US 2002-346598P	P 20020107
JP 2005524621	T	20050810	US 2002-346598P	P 20020107
			WO 2003-US366	W 20030107


L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 AT 327236 T 20060615 AT 2003-729359 20030107
 PT 1474425 T 20060929 US 2002-346598P P 20020107
 EP 1707566 A1 20061004 EP 2003-729359 P 20020107
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 WO 2004063336 A2 20040729 EP 2003-729359 A3 20030107
 WO 2004063336 A3 20040826 WO 2004-US293 20040107
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
 US 2004186127 A1 20040923 US 2004-753261 20040107
 ZA 2004006272 A 20051116 US 2002-346598P P 20020107
 NO 2004003290 A 20040922 US 2003-US366 A2 20030107
 US 2004-3290 20040806
 US 2002-346598P P 20020107
 WO 2003-US366 W 20030107

PATENT FAMILY INFORMATION:
 FAN 2004:780361
 PATENT NO. KIND DATE APPLICATION NO. DATE

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2004186127	A1	20040923	US 2004-753261	20040107
			US 2002-346598P	P 20020107
			WO 2003-US366	A2 20030107
WO 2003057696	A1	20030717	WO 2003-US366	20030107
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1707566	A1	20061004	EP 2006-5483	20030107
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2002-346598P	P	20020107	US 2002-346598P	P 20020107
EP 2003-729359	A3	20030107		


OS MARPAT 139:117268
 ED Entered STN: 18 Jul 2003
 GI

L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




AB Indolyldeazapurines, such as I [R1 = H, NH2, alkylamino, acylamino, etc.; R2 = H, amino, alkoxy, alkyl, etc.; R3 = H, CN, halogen, heteroaryl, amino, carbamoyl, etc.], were prepared for therapeutic use as inhibitors of cell adhesion, mol. expression and inflammatory cytokine signal transduction. These deazapurines are useful in the treatment of inflammatory, autoimmune, proliferative, central nervous system and cardiovascular diseases, such as rheumatoid arthritis, ulcerative colitis, multiple sclerosis, asthma, psoriasis, allograft rejection/graft vs. host disease, idiopathic thrombocytopenia, allergic rhinitis, atopic dermatitis, systemic lupus, glomerulonephritis, diabetes, ulcerative colitis/Crohn's disease, erythematous, eczema, urticaria, myasthenia gravis, idiopathic thrombocytopenia purpura and cancer. Thus, deazapurine II was prepared via a coupling reaction of the corresponding halodeazapurine with 2-(tributylstannyl)-1H-indole-1-carboxylic acid 1,1-dimethylethyl ester. The prepared deazapurines were assayed for cellular cytokine inhibition using human umbilical vein endothelial cells (HUVEC).
 IT 562081-62-3P, ER 806393 562083-38-9P, ER 806644
 562083-47-0P, ER 807586 562083-59-4P, ER 807790
 562083-81-2P, ER 808036 562083-93-6P, ER 808281
 562084-05-3P, ER 807835
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (preparation of indolyldeazapurines for use in pharmaceutical compns. for treatment of inflammatory, autoimmune and proliferative diseases)
 RN 562081-62-3 CAPLUS
 CN L-Alanine,
 N-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]carbonyl]-3-(ethylphenylamino)-, methyl ester (9CI) (CA INDEX NAME)
 Absolute stereochemistry.

L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 562083-38-9 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridin-5-amine,
 2-methyl-7-[5-(phenylethynyl)-1H-indol-2-yl]- (9CI) (CA INDEX NAME)
 RN 562083-47-0 CAPLUS
 CN Cyclohexanone,
 4-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]methylamino]- (9CI) (CA INDEX NAME)




RN 562083-59-4 CAPLUS
 CN Cyclohexanol, 4-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]methylamino]-, trans- (9CI) (CA INDEX NAME)
 Relative stereochemistry.

L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 562083-81-2 CAPLUS
CN 1H-Imidazo[4,5-b]pyridin-5-amine,
7-[5-[(cyclohexylthio)methyl]-1H-indol-2-
yl]-2-methyl- (9CI) (CA INDEX NAME)



RN 562083-93-6 CAPLUS
CN 1H-Imidazo[4,5-b]pyridin-5-amine,
7-[5-[(1E)-2-cyclohexylethenyl]-1H-indol-
2-yl]-2-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 562084-05-3 CAPLUS
CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[(methyl(4-
methylenecyclohexyl)amino)methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)


L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

562083-50-5P, ER 807789 562083-74-3P, ER 807837
562083-83-4P, ER 808082 562083-84-5P, ER 808083
562083-85-6P, ER 808103 562083-87-8P, ER 808040
562083-90-3P, ER 808128 562083-94-7P, ER 808469
562083-98-1P, ER 809047 562083-99-2P, IC 261
562084-00-8P, IC 395 562084-01-9P, IC 375
562084-02-0P, IC 380 562084-03-1P, IC 416
562084-04-2P, ER 807546
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(prepn. of indolyldeazapurines for use in pharmaceutical compns. for
treatment of inflammatory, autoimmune and proliferative diseases)
RN 561307-06-0 CAPLUS
CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-
[(methyl(phenylmethyl)amino)methyl]-1H-indol-2-yl]- (9CI) (CA INDEX
NAME)




RN 561307-07-1 CAPLUS
CN 1H-Imidazo[4,5-b]pyridin-5-amine,
7-[5-[(3-chlorophenyl)methyl]methylami
no)methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 562077-48-9 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-
yl)- (9CI) (CA INDEX NAME)

L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




IT 561307-06-0P 561307-07-1P 562077-48-9P, ER
806014 562077-49-0P, ER 806006 562077-50-3P, ER 805985
562077-51-4P, ER 805984 562077-52-5P, ER 806002
562077-53-6P, ER 805989 562077-54-7P, ER 805971
562077-55-8P, ER 806007 562077-56-9P, ER 806011
562077-57-0P, ER 805972 562077-59-2P, ER 805997
562077-61-6P, ER 806010 562077-97-8P, ER 806123
562078-00-6P, ER 806136 562078-08-4P, ER 806221
562078-10-8P, ER 806220 562078-35-7P, ER 806224
562078-70-0P, ER 806228 562079-06-5P, ER 806276
562079-30-5P, ER 806275 562079-63-4P, ER 806273
562079-95-2P, ER 806317 562080-38-0P, ER 806320
562080-50-6P, ER 806329 562081-01-0P, ER 806333
562081-02-1P, ER 806336 562081-16-7P, ER 806358
562081-19-0P, ER 806359 562081-25-8P, ER 806363
562081-26-9P, ER 806362 562081-27-0P, ER 806361
562081-28-1P, ER 806368 562081-31-6P, ER 806372
562081-32-7P, ER 806373 562081-59-8P, ER 806374
562081-60-1P, ER 806375 562081-61-2P, ER 806383
562081-63-4P, ER 806402 562081-64-5P, ER 806417
562081-67-8P, ER 806419 562081-83-8P, ER 806421
562081-88-3P, ER 806435 562081-89-4P, ER 806437
562081-90-7P, ER 806569 562081-91-8P, ER 806609
562081-92-9P, ER 806610 562081-93-0P, ER 806647
562081-94-1P, ER 806653 562081-95-2P, ER 806671
562081-96-3P, ER 806790 562081-97-4P, ER 806820
562081-98-5P, ER 806839 562082-38-6P, ER 806840
562082-59-1P, ER 806841 562082-68-2P, ER 806842
562082-85-3P, ER 806843 562082-86-4P, ER 806844
562082-87-5P, ER 806860 562082-88-6P, ER 806901
562082-89-7P, ER 806902 562082-90-0P, ER 806903
562082-91-1P, ER 806905 562082-92-2P, ER 806987
562082-93-3P, ER 807014 562082-94-4P, ER 807140
562082-95-5P, ER 807183 562082-96-6P, ER 807240
562082-97-7P, ER 807450 562082-98-8P, ER 807451
562083-00-5P, ER 807452 562083-01-6P, ER 807460
562083-02-7P, ER 807573 562083-04-9P, ER 806286
562083-10-7P, ER 806287 562083-34-5P, ER 806311
562083-35-6P, ER 806355 562083-36-7P, ER 806401
562083-37-8P, ER 806404 562083-39-0P, ER 806645
562083-41-4P, ER 806646 562083-42-5P, ER 806095
562083-43-6P, ER 806420 562083-44-7P, ER 806432
562083-46-9P, ER 807313 562083-49-2P, ER 807759


L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 562077-49-0 CAPLUS
CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-(1H-indol-2-yl)-2-(trifluoromethyl)-
(9CI) (CA INDEX NAME)



RN 562077-50-3 CAPLUS
CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-ethyl-7-(1H-indol-2-yl)- (9CI) (CA
INDEX NAME)




RN 562077-51-4 CAPLUS
CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-(1H-indol-2-yl)-2-propyl- (9CI) (CA
INDEX NAME)




RN 562077-52-5 CAPLUS
CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-butyl-7-(1H-indol-2-yl)- (9CI) (CA
INDEX NAME)


L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 562077-53-6 CAPLUS
CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-(1H-indol-2-yl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 562077-54-7 CAPLUS
CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-(1H-indol-2-yl)-2-[(4-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 562077-55-8 CAPLUS
CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[5-(4-morpholinylmethyl)-1H-indol-2-yl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)


L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 562077-56-9 CAPLUS
CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-ethoxy-7-[5-(4-morpholinylmethyl)-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562077-57-0 CAPLUS
CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-[(4-methylphenyl)methyl]-7-[5-(4-morpholinylmethyl)-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562077-59-2 CAPLUS
CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-[4-(methylthio)phenyl]-7-[5-(4-morpholinylmethyl)-1H-indol-2-yl]- (9CI) (CA INDEX NAME)


L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 562077-61-6 CAPLUS
CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-(4-methoxyphenyl)-7-[5-(4-morpholinylmethyl)-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562077-97-8 CAPLUS
CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-(1-piperidinylmethyl)-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562078-00-6 CAPLUS
CN Piperazine, 1-acetyl-4-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]- (9CI) (CA INDEX NAME)


L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 562078-08-4 CAPLUS
CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[5-[[[4-(4-methoxyphenyl)methyl]amino]methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 562078-10-8 CAPLUS
CN Methanone, [1-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]-4-piperidinyl]phenyl- (9CI) (CA INDEX NAME)




RN 562078-35-7 CAPLUS
CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[5-[[[bis(2-methoxyethyl)amino]methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)


L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 562078-70-0 CAPLUS
CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[[methyl(2-(2-pyridinyl)ethyl)amino]methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562079-06-5 CAPLUS
CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 562079-30-5 CAPLUS
CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[[methyl(3,4,5-trimethoxyphenyl)amino]methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)

L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 562080-50-6 CAPLUS
CN Butanamide, 2-[[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]amino]-4-(methylthio)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 562081-01-0 CAPLUS
CN L-Alanine, N-[[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]-3-(ethylphenylamino)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 562081-02-1 CAPLUS
CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[[5-[[ethyl(phenylmethyl)amino]methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)


L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 562079-63-4 CAPLUS
CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[[methyl(2-phenylethyl)amino]methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562079-95-2 CAPLUS
CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[[[2-(2-pyridinyl)ethyl]amino]methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562080-38-0 CAPLUS
CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[[5-[[[(4-chlorophenyl)methyl]amino]methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)


L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 562081-16-7 CAPLUS
CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[[5-[[[ethyl(phenylamino)methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 562081-19-0 CAPLUS
CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[[[2-(2-phenylethyl)ethyl]amino]methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562081-25-8 CAPLUS
CN Benzenesulfonamide, 4-[[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]amino]methyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 562081-26-9 CAPLUS
CN Benzenepropanamide, α -([2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl)amino]-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 562081-27-0 CAPLUS
CN 1H-Indole-3-propanamide, α -([2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl)amino]-, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 562081-60-1 CAPLUS
CN 1H-Indole-5-carboxamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 562081-61-2 CAPLUS
CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-([methyl(2-methylpropyl)amino]methyl)-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562081-63-4 CAPLUS
CN 1H-Indole-5-carboxamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 562081-28-1 CAPLUS
CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-([phenylamino]methyl)-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562081-31-6 CAPLUS
CN Methanone, [1-([2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl)-4-piperidinyl](4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 562081-32-7 CAPLUS
CN Methanone, [1-([2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl)-4-piperidinyl](4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 562081-59-8 CAPLUS
CN Methanone, [1-([2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl)-4-piperidinyl](4-fluorophenyl)- (9CI) (CA INDEX NAME)




L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 562081-64-5 CAPLUS
CN 1H-Indole-5-carboxamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 562081-67-8 CAPLUS
CN Glycine, N-([2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl)-N-(phenylmethyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 562081-83-8 CAPLUS
CN 1H-Indole-5-carboxamide, N-([2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl)-N-(phenylmethyl)-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 562081-88-3 CAPLUS
 CN 1H-imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[[methyl((1R)-1-phenylethyl)amino]methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 562081-89-4 CAPLUS
 CN 1H-imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[[methyl((1S)-1-phenylethyl)amino]methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 562081-93-0 CAPLUS
 CN 1H-indole-5-carboxamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-[(1S)-2-(ethylamino)-1-[(ethylphenylamino)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 562081-94-1 CAPLUS
 CN 1H-indole-5-carboxamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-[(2-(ethylphenylamino)ethyl)]- (9CI) (CA INDEX NAME)




RN 562081-95-2 CAPLUS
 CN 1H-indole-5-carboxamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-[2-methoxy-1-(methoxymethyl)ethyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 562081-90-7 CAPLUS
 CN Piperazine, 1-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]carbonyl]-4-phenyl- (9CI) (CA INDEX NAME)




RN 562081-91-8 CAPLUS
 CN 1H-indole-5-carboxamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-[(1S)-1-[(ethylphenylamino)methyl]-2-(methylamino)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 562081-92-9 CAPLUS
 CN 1H-imidazo[4,5-b]pyridin-5-amine, 7-[5-[[[(3-methoxyphenyl)methyl]methylam]

L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 562081-96-3 CAPLUS
 CN 1H-indole-5-carboxamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-[(1S)-1-[(ethylphenylamino)methyl]-2-(methylamino)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 562081-97-4 CAPLUS
 CN 1H-indole-5-carboxamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-[(1S)-1-[(ethylamino)carbonyl]-3-phenylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 562081-98-5 CAPLUS
 CN 1H-indole-5-carboxamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-[(2-chlorophenyl)methyl]-N-methyl- (9CI) (CA INDEX NAME)


L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 562082-38-6 CAPLUS
 CN 1H-Indole-5-carboxamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-((3-chlorophenyl)methyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 562082-59-1 CAPLUS
 CN 1H-Indole-5-carboxamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-((4-chlorophenyl)methyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 562082-68-2 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[6-([methyl(phenylmethyl)amino)methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)


L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 562082-88-6 CAPLUS
 CN Piperidine, 1-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-6-yl]carbonyl]-4-(4-fluorobenzoyl)- (9CI) (CA INDEX NAME)




RN 562082-89-7 CAPLUS
 CN Morpholine, 4-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-6-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 562082-90-0 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[5-[[[(2-chlorophenyl)methyl]methylamino]methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)


L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 562082-85-3 CAPLUS
 CN Methanone, [1-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-6-yl]methyl]-4-piperidinyl]-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 562082-86-4 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[6-(4-morpholinylmethyl)-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562082-87-5 CAPLUS
 CN 1H-Indole-5-carboxamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-[(1R)-1-[(ethylamino)carbonyl]-3-phenylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 562082-91-1 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[5-[[[(4-chlorophenyl)methyl]methylamino]methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 562082-92-2 CAPLUS
 CN 1H-Indole-5-carboxamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-[(4-methoxyphenyl)methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 562082-93-3 CAPLUS
 CN 1H-Indole-5-carboxamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-methyl- (9CI) (CA INDEX NAME)


L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 562082-94-4 CAPLUS
 CN 1H-imidazo[4,5-b]pyridin-5-amine,
 7-[5-[[[(4-methoxyphenyl)methyl]methylamino]methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 562082-95-5 CAPLUS
 CN 1H-indole-5-carboxamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-[(2-methoxyphenyl)methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 562082-96-6 CAPLUS
 CN 1H-imidazo[4,5-b]pyridin-5-amine,
 7-[5-[[[(2-methoxyphenyl)methyl]methylamino]methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)


L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 562083-01-6 CAPLUS
 CN 1H-imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[[methyl[(2-(trifluoromethoxy)phenyl)methyl]amino]methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562083-02-7 CAPLUS
 CN 1H-imidazo[4,5-b]pyridin-5-amine,
 7-[5-[[[(2-furanylmethyl)methylamino]methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 562083-04-9 CAPLUS
 CN 1H-isoindole-1,3(2H)-dione, 2-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]- (9CI) (CA INDEX NAME)


L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 562082-97-7 CAPLUS
 CN 1H-imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[[methyl[(3-(trifluoromethoxy)phenyl)methyl]amino]methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562082-98-8 CAPLUS
 CN 1H-imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[[methyl[(4-(trifluoromethoxy)phenyl)methyl]amino]methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562083-00-5 CAPLUS
 CN 1H-imidazo[4,5-b]pyridin-5-amine, 7-[5-[[[(3,4-dichlorophenyl)methyl]methylamino]methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)


L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 562083-10-7 CAPLUS
 CN 1H-imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[[methyl[(2-(trifluoromethyl)phenoxy)methyl]amino]methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562083-34-5 CAPLUS
 CN 1H-imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[[methyl[(phenylthio)methyl]amino]methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562083-35-6 CAPLUS
 CN 4-Piperidinone,
 1-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]- (9CI) (CA INDEX NAME)


L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 562083-36-7 CAPLUS
 CN 1H-imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[(1-oxido-4-thiomorpholinyl)methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562083-37-8 CAPLUS
 CN 1H-imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[(phenylmethoxy)methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562083-39-0 CAPLUS
 CN 1H-imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[(1Z)-2-phenylethenyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 562083-44-7 CAPLUS
 CN Benzamide, N-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 562083-46-9 CAPLUS
 CN Benzamide, N-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 562083-49-2 CAPLUS
 CN Cyclohexanone, 4-[[[2-(5-amino-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]methylamino]- (9CI) (CA INDEX NAME)


L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 562083-41-4 CAPLUS
 CN 1H-imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[(2-phenylethyl)-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562083-42-5 CAPLUS
 CN 1H-indole-5-methanol, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)- (9CI) (CA INDEX NAME)




RN 562083-43-6 CAPLUS
 CN L-Alanine, N-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]carbonyl]-3-(ethylphenylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 562083-50-5 CAPLUS
 CN Cyclohexanone, 4-[[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]methylamino]-, O-methylloxime (9CI) (CA INDEX NAME)



RN 562083-74-3 CAPLUS
 CN Cyclohexanol, 4-[[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]methylamino]-1-methyl- (9CI) (CA INDEX NAME)




RN 562083-83-4 CAPLUS
 CN 1H-imidazo[4,5-b]pyridin-5-amine, 7-[5-[(cyclohexylsulfonyl)methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 562083-84-5 CAPLUS
 CN 1H-imidazo[4,5-b]pyridin-5-amine, 7-[5-[(cyclohexylsulfonyl)methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)


L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)



RN 562083-85-6 CAPLUS
CN 1H-imidazo[4,5-b]pyridin-5-amine,
7-[(5-[(cyclohexyloxy)methyl]-1H-indol-2-yl)-2-methyl- (9CI)] (CA INDEX NAME)




RN 562083-87-8 CAPLUS
CN 1H-imidazo[4,5-b]pyridin-5-amine,
7-[(5-[(cyclohexylmethylamino)methyl]-1H-indol-2-yl)-N,N,2-dimethyl- (9CI)] (CA INDEX NAME)




RN 562083-90-3 CAPLUS
CN 1H-imidazo[4,5-b]pyridin-5-amine, 7-[(5-[(3-cyclohexen-1-ylmethylamino)methyl]-1H-indol-2-yl)-2-methyl- (9CI)] (CA INDEX NAME)


L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)




RN 562084-00-8 CAPLUS
CN Carbamic acid, [7-[(1H-indol-2-yl)-1H-imidazo[4,5-b]pyridin-5-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 562084-01-9 CAPLUS
CN 1H-imidazo[4,5-b]pyridin-5-amine, 7-[(1H-indol-2-yl)- (9CI)] (CA INDEX NAME)




RN 562084-02-0 CAPLUS
CN 2H-imidazo[4,5-b]pyridin-2-one, 5-amino-1,3-dihydro-7-[(1H-indol-2-yl)- (9CI)] (CA INDEX NAME)




RN 562084-03-1 CAPLUS
CN 1H-imidazo[4,5-b]pyridine-2,5-diamine, 7-[(1H-indol-2-yl)- (9CI)] (CA INDEX NAME)


L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



RN 562083-94-7 CAPLUS
CN 1H-imidazo[4,5-b]pyridin-5-amine,
7-[(5-[(2-cyclohexylethyl)-1H-indol-2-yl)-2-methyl- (9CI)] (CA INDEX NAME)




RN 562083-98-1 CAPLUS
CN 1H-indole-5-carboxylic acid,
2-[(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)- (9CI)] (CA INDEX NAME)




RN 562083-99-2 CAPLUS
CN 1H-imidazo[4,5-b]pyridine, 7-[(1H-indol-2-yl)- (9CI)] (CA INDEX NAME)

L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)




RN 562084-04-2 CAPLUS
CN 5H-imidazo[4,5-b]pyridin-5-one, 1,4-dihydro-2-methyl-7-[(5-[(methyl(phenylmethyl)amino)methyl]-1H-indol-2-yl)- (9CI)] (CA INDEX NAME)




IT 561307-19-5P 561307-20-8P 561307-21-9P
561307-22-0P 561307-23-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of indolyldeazapurines for use in pharmaceutical compns.)

for treatment of inflammatory, autoimmune and proliferative diseases)
RN 561307-19-3 CAPLUS
CN 1H-imidazo[4,5-b]pyridin-5-amine, 7-[(5-[(1,1-dimethylethyl)dimethylsilyloxy)methyl]-1H-indol-2-yl)-2-methyl- (9CI)] (CA INDEX NAME)




RN 561307-20-8 CAPLUS
CN 3H-imidazo[4,5-b]pyridine-3-carboxylic acid, 5-[[bis[(1,1-dimethylethyl)dimethylsilyloxy)methyl]-1H-indol-2-yl)-2-methyl- (9CI)] (CA INDEX NAME)

L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 dimethylethoxy)carbonyl]amino]-7-[1-[(1,1-dimethylethoxy)carbonyl]-5-(hydroxymethyl)-1H-indol-2-yl]-2-methyl-, 1,1-dimethylethyl ester (9CI)
 (CA INDEX NAME)




RN 561307-21-9 CAPLUS
 CN 3H-imidazo[4,5-b]pyridine-3-carboxylic acid, 5-bis[(1,1-dimethylethoxy)carbonyl]amino]-7-[5-(chloromethyl)-1-[(1,1-dimethylethoxy)carbonyl]-1H-indol-2-yl]-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 561307-22-0 CAPLUS
 CN 3H-imidazo[4,5-b]pyridine-3-carboxylic acid, 5-bis[(1,1-

L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 dimethylethoxy)carbonyl]amino]-7-[1-[(1,1-dimethylethoxy)carbonyl]-5-formyl-1H-indol-2-yl]-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 561307-23-1 CAPLUS
 CN 1H-Indole-1,5-dicarboxylic acid, 2-[5-bis[(1,1-dimethylethoxy)carbonyl]amino]-3-[(1,1-dimethylethoxy)carbonyl]-2-methyl-3H-imidazo[4,5-b]pyridin-7-yl]-, 1-(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☒ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.